QM-B and QM-C Hysterectomy for Early Cervical Cancer
QM-B and QM-C Hysterectomy for Early Cervical Cancer
The goal of this clinical research study is to compare the long-term outcomes and safety of
 Querleu-Morrow-B(QM-B) and Querleu-Morrow-C(QM-C) hysterectomy for early cervical cancer. In
 this study, the surgical approach for QM-B and QM-C hysterectomy will be abdominal.
Primary Objective:

 To compare 5-year overall survival and 5-year disease-free survival amongst patients who
 undergo a QM-B hysterectomy versus those who undergo a QM-C hysterectomy for early stage
 cervical cancer.

 Secondary Objectives:

 Compare operation time between arms. Compare blood loss between arms. Compare blood
 transfusion between arms. Compare intraoperative complications between arms. Compare
 postoperative complications between arms. Compare quality of lifes between arms.
Inclusion Criteria:

 -  Patients who have signed an approved Informed Consent

 -  18.5≤BMI<28

 -  Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or
 adenosquamous carcinoma of the uterine cervix;

 -  Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), stage
 IA2, stage IB1, stage IB2, or stage IIA1 disease(FIGO 2018).

 -  Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1.

 -  Patients undergoing the Non-Fertility-Sparing surgery.

 -  Patients undergoing abdominal surgery.

 Exclusion Criteria:

 -  The life expectancy of the patient is less than 6 months.

 -  Patients with serious medical diseases.

 -  Patients with contraindications to surgery or anesthesia.

 -  Preoperative imaging studies suggest metastasis to pelvic lymph nodes or para-aortic
 lymph nodes.

 -  Patient asks to preserve fertility.

 -  The patient requested direct radiation therapy.

 -  Patients with adjuvant radiotherapy or chemotherapy before surgery.

 -  Patients judged by the investigator to be unsuitable to participate in this trial.